Arcus Biosciences (RCUS) Cash from Investing Activities (2017 - 2026)

Arcus Biosciences' Cash from Investing Activities history runs 10 years deep, the most recent figure standing at $114.0 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 256.25% year-over-year to $114.0 million in Q1 2026; TTM through Mar 2026 was $148.0 million, a 26.5% increase from a year earlier, with the FY2025 full-year figure at $66.0 million, up 178.57% from the prior year.
• Cash from Investing Activities advanced to $114.0 million in Q1 2026 per RCUS's latest filing, from -$182.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $137.0 million in Q2 2025 and bottomed at -$268.0 million in Q1 2022.
• The 5-year median for Cash from Investing Activities is $28.0 million (2023), against an average of -$7.2 million.
• Across the five-year window, Cash from Investing Activities slumped 7259.51% in 2022 and soared 372.41% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at $47.0 million in 2022, then sank by 40.43% to $28.0 million in 2023, then jumped by 82.14% to $51.0 million in 2024, then slumped by 456.86% to -$182.0 million in 2025, then jumped by 162.64% to $114.0 million in 2026.
• Per Business Quant, the three latest RCUS Cash from Investing Activities figures stand at $114.0 million (Q1 2026), -$182.0 million (Q4 2025), and $79.0 million (Q3 2025).